Scarica l'app Stockscreener
1.14
8.06%
-0.10
Dopo l'orario di chiusura:
1.12
-0.02
-1.75%
Precedente Chiudi:
$1.24
Aprire:
$1.26
Volume 24 ore:
3.21M
Relative Volume:
0.39
Capitalizzazione di mercato:
$14.99M
Reddito:
-
Utile/perdita netta:
$-7.51M
Rapporto P/E:
-0.8636
EPS:
-1.32
Flusso di cassa netto:
$-8.02M
1 W Prestazione:
+20.71%
1M Prestazione:
-8.06%
6M Prestazione:
-9.52%
1 anno Prestazione:
-11.63%
Intervallo 1D:
$1.02
$1.29
Intervallo di 1 settimana:
$0.8401
$1.29
Portata 52W:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Nome
Hoth Therapeutics Inc
Settore
Industria
Telefono
(646)756-2997
Indirizzo
590 MADISON AVENUE, NEW YORK, NY
Confronta HOTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.14 | 14.99M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.64 | 126.25B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.15 | 75.12B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.49 | 38.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.23 | 32.26B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
262.21 | 28.10B | 3.32B | -860.46M | -1.04B | -8.32 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-10-15 | Iniziato | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Borsa (HOTH) Ultime notizie
Hoth Therapeutics reports HT-001 cream success in skin toxicity - Investing.com India
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting - PR Newswire
Hoth Therapeutics’ (HOTH) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Hoth Therapeutics Announces Positive Findings On GDNF's Potential As A Game-Changer In Obesity Treatment And Reduced Fatty Liver Disease - Marketscreener.com
Can Hoth's GDNF Protein Disrupt the $70B Obesity Drug Market? Preclinical Results Show Unique Advantage - StockTitan
Financial Contrast: Emmaus Life Sciences (OTCMKTS:EMMA) and Hoth Therapeutics (NASDAQ:HOTH) - Defense World
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - MSN
Hoth Therapeutics (NASDAQ:HOTH) Given Buy Rating at D. Boral Capital - Defense World
Hoth Therapeutics to Present at the LD Micro Main Event (XII) - ACCESS Newswire
What to expect from HOTH’s earnings report this quarter? - US Post News
Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic - Contract Pharma
HOTH's Cancer Breakthrough: Strategic Alliance Accelerates Novel HT-KIT Therapeutic Research - StockTitan
Hoth Therapeutics expands at-the-market offering by $5 million - Investing.com Australia
Research Analysts Set Expectations for HOTH FY2024 Earnings - Defense World
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at HC Wainwright - Defense World
Hoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsNew York, NY – January 24, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced today that it has successfully regained compliance with the minimum bid price requirement s - Defense World
Financial Contrast: Hoth Therapeutics (NASDAQ:HOTH) vs. Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Hoth Therapeutics expands cancer drug patent portfolio - MSN
Hoth Therapeutics Breaks New Ground! Nasdaq Compliance Achieved! - Mi Valle
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements - PR Newswire
Hoth Therapeutics Regains Nasdaq Compliance, Secures Exchange Listing Status - StockTitan
Hoth Therapeutics expands cancer drug patent portfolio By Investing.com - Investing.com Australia
Hoth Therapeutics Acquires New Patent Applications - Contract Pharma
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications - PR Newswire
Hoth Therapeutics Expands Cancer Drug Patent Portfolio, Strengthens HT-001 Development Strategy - StockTitan
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 - PR Newswire
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More - MSN
Shares Of This Micro Cap More Than Doubled Today - MSN
3 Penny Stocks to Watch Now, 1/9/25 - TipRanks
Hoth Therapeutics maintains strong cash position, no offering plans By Investing.com - Investing.com Nigeria
Hoth Therapeutics Shares Recover; Company Has No Plans for Offering - MarketWatch
Hoth Therapeutics maintains strong cash position, no offering plans - Investing.com
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries - PR Newswire
S&P 500 E-Mini (ESM23) Quote - The Globe and Mail
Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s Excited - Asianet Newsable
Dow Jones Transportations Average (DOWT) QuotePress Release - The Globe and Mail
Dow Jones Global (DOWG) QuotePress Release - The Globe and Mail
Hoth reports 100% success in cancer skin toxicity trial By Investing.com - Investing.com South Africa
Hoth Therapeutics Inc Azioni (HOTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):